Refine
Year of publication
- 2024 (41)
- 2023 (89)
- 2022 (133)
- 2021 (136)
- 2020 (168)
- 2019 (193)
- 2018 (168)
- 2017 (153)
- 2016 (154)
- 2015 (162)
- 2014 (160)
- 2013 (170)
- 2012 (161)
- 2011 (183)
- 2010 (179)
- 2009 (179)
- 2008 (149)
- 2007 (137)
- 2006 (129)
- 2005 (122)
- 2004 (150)
- 2003 (95)
- 2002 (123)
- 2001 (103)
- 2000 (102)
- 1999 (109)
- 1998 (98)
- 1997 (96)
- 1996 (81)
- 1995 (78)
- 1994 (86)
- 1993 (59)
- 1992 (54)
- 1991 (29)
- 1990 (39)
- 1989 (44)
- 1988 (56)
- 1987 (32)
- 1986 (19)
- 1985 (33)
- 1984 (22)
- 1983 (20)
- 1982 (29)
- 1981 (20)
- 1980 (36)
- 1979 (24)
- 1978 (34)
- 1977 (14)
- 1976 (13)
- 1975 (12)
- 1974 (3)
- 1973 (2)
- 1972 (2)
- 1971 (1)
- 1968 (1)
Institute
- Fachbereich Medizintechnik und Technomathematik (1564)
- Fachbereich Elektrotechnik und Informationstechnik (711)
- IfB - Institut für Bioengineering (563)
- Fachbereich Energietechnik (561)
- Fachbereich Chemie und Biotechnologie (537)
- INB - Institut für Nano- und Biotechnologien (533)
- Fachbereich Luft- und Raumfahrttechnik (480)
- Fachbereich Maschinenbau und Mechatronik (262)
- Fachbereich Wirtschaftswissenschaften (205)
- Solar-Institut Jülich (161)
Has Fulltext
- no (4685) (remove)
Language
- English (4685) (remove)
Document Type
- Article (3193)
- Conference Proceeding (1033)
- Part of a Book (191)
- Book (144)
- Doctoral Thesis (30)
- Conference: Meeting Abstract (28)
- Patent (25)
- Other (10)
- Report (9)
- Conference Poster (5)
Keywords
- Gamification (6)
- avalanche (6)
- Earthquake (5)
- Enterprise Architecture (5)
- MINLP (5)
- solar sail (5)
- Additive manufacturing (4)
- Diversity Management (4)
- Energy storage (4)
- Engineering optimization (4)
With its need for high SNR and short acquisition times, Cardiac MRI (CMR) is an intriguing target application for ultrahigh field MRI. Due to the sheer size of the upper torso, however, the known RF issues of 7T MRI are also most prominent in CMR. Recent years brought substantial progress but the full potential of the ultrahigh field for CMR is yet to be exploited. Parallel transmission (pTx) is a promising approach in this context and several groups have already reported B1 shimming for 7T CMR. In such a static pTx application amplitudes and phases of all Tx channels are adjusted individually but otherwise imaging techniques established in current clinical practice 1.5 T and 3 T are applied. More advanced forms of pTx as spatially selective excitation (SSE) using Transmit SENSE promise additional benefits like faster imaging with reduced fields of view or improved SAR control. SSE requires the full dynamic capabilities of pTx, however, and for the majority of today's implemented pTx hardware the internal synchronization of the Tx array does not easily permit external triggering as needed for CMR. Here we report a software solution to this problem and demonstrate the feasibility of CINE CMR at 7 T using a Tx array.
Handbook of space technology
(2009)
Analysis of the long-term effect of the MBST® nuclear magnetic resonance therapy on gonarthrosis
(2016)
Bioconjugates containing the GnRH-III hormone decapeptide as a targeting moiety are able to deliver chemotherapeutic agents specifically to cancer cells expressing GnRH receptors, thereby increasing their local efficacy while limiting the peripheral toxicity. However, the number of GnRH receptors on cancer cells is limited and they desensitize under continuous hormone treatment. A possible approach to increase the receptor mediated tumor targeting and consequently the cytostatic effect of the bioconjugates would be the attachment of more than one chemotherapeutic agent to one GnRH-III molecule. Here we report on the design, synthesis and biochemical characterization of multifunctional bioconjugates containing GnRH-III as a targeting moiety and daunorubicin as a chemotherapeutic agent. Two different drug design approaches were pursued. The first one was based on the bifunctional [4Lys]-GnRH-III (Glp-His-Trp-Lys-His-Asp-Trp-Lys-Pro-Gly-NH2) containing two lysine residues in positions 4 and 8, whose ϵ-amino groups were used for the coupling of daunorubicin. In the second drug design, the native GnRH-III (Glp-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2) was used as a scaffold; an additional lysine residue was coupled to the ϵ-amino group of 8Lys in order to generate two free amino groups available for conjugation of daunorubicin. The in vitro stability/degradation of all synthesized compounds was investigated in human serum, as well as in the presence of rat liver lysosomal homogenate. Their cellular uptake was determined on human breast cancer cells and the cytostatic effect was evaluated on human breast, colon and prostate cancer cell lines. Compared with a monofunctional compound, both drug design approaches resulted in multifunctional bioconjugates with increased cytostatic effect.